<h4>Objective</h4>To investigate the impact of proprotein convertase subtilisin kexin type-9 inhibitor (PCSK9i) on patients with metabolic dysfunction-associated fatty liver disease (MAFLD) combined with type 2 diabetes mellitus (T2DM).<h4>Methods</h4>This retrospective study reviewed the clinical data of 60 inpatients with MAFLD combined with T2DM from the electronic medical record (EMR) system. Here, PCSK9 is linked to type 2 diabetes mellitus.